Zydus faces stiff competition for blockbuster drug in US from Teva Pharma

Ahmedabad-based pharma major Cadila Healthcare's blockbuster generic drug for treating ulcerative colitis is in for stiff competition from Israeli drug major Teva Pharmaceutical Industries.

Teva launched the generic version of Irish firm Shire’s Lialda in the US earlier this week.

Analysts expect the margins of the drug to shrink as competition rises in the US market.  Apart from Teva, Mylan and Amneal are the other probable filers and are expected to launch their products in 2018-19. 

Deepak Malik, analyst with Edelweiss Securities, said: “Once competing products start coming into the market, the drug largely loses its attractiveness and becomes like any other generic